Eloralintide vs Selank
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
EloralintideCognitive Enhancement
Selank- Summary
- Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
- Selank is a synthetic heptapeptide analog of tuftsin developed in Russia. It is a potent anxiolytic that reduces anxiety and enhances cognitive function without sedation or addiction. It is approved for clinical use in Russia for anxiety disorders.
- Half-Life
- ~7 days (estimated, long-acting design)
- Minutes (but effects persist for hours)
- Admin Route
- SubQ
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- Under investigation in Phase 1/2 trials
- 250–500 mcg
- Frequency
- Once weekly
- 1–3 times daily
- Key Benefits
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
- Reduces anxiety without sedation
- Enhances memory and learning
- Improves focus and concentration
- Stabilizes mood
- Reduces physiological stress response
- May enhance motivation
- No addiction potential or withdrawal
- Fast-acting — effects within 20–30 minutes
- Approved clinically in Russia for anxiety disorders
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- +1 more
- Mild sedation at higher doses (paradoxical)
- Fatigue (rare)
- Irritability during discontinuation (uncommon)
- Stacks With
- —
- —